Patents Represented by Attorney Incyte Pharmaceuticals
  • Patent number: 6063594
    Abstract: The present invention provides a novel anion channel (NANCH) and polynucleotides which identify and encode NANCH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NANCH and a method for producing NANCH. The invention also provides for agonists, antibodies, or antagonists specifically binding NANCH, and their use, in the prevention and treatment of diseases associated with expression of NANCH. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NANCH for the treatment of diseases associated with the expression of NANCH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NANCH.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: May 16, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Surya K. Goli
  • Patent number: 6063767
    Abstract: The invention provides two human phospholipid binding proteins (PLBP) and polynucleotides which identify and encode PLBP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating and preventing disorders associated with expression of PLBP.
    Type: Grant
    Filed: December 9, 1998
    Date of Patent: May 16, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Jennifer L. Hillman, Neil C. Corley, Purvi Shah
  • Patent number: 6060297
    Abstract: The present invention provides a human Rho protein (HRHO) and polynucleotides which identify and encode HRHO. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing HRHO and for treating or preventing disorders associated with expression of HRHO.
    Type: Grant
    Filed: April 17, 1997
    Date of Patent: May 9, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Patent number: 6060239
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel cellubrevins (cb). The present invention also provides for antisense molecules to the nucleotide sequences which encode cbs, expression vectors for the production of purified CBs, antibodies capable of binding specifically to CBs, hybridization probes or oligonucleotides for the detecting the induction of CB encoding nucleotide sequences, genetically engineered host cells for the expression of CBs, diagnostic tests for activated, inflamed or diseased cells and/or tissues based on CB-encoding nucleic acid molecules and antibodies capable of binding specifically to CBs.
    Type: Grant
    Filed: March 22, 1996
    Date of Patent: May 9, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Susan G. Stuart, Phillip R. Hawkins, Jeffrey J. Seilhamer, Lynn E. Murry
  • Patent number: 6060250
    Abstract: The invention provides three human transferases (HUTRAN) and polynucleotides which identify and encode HUTRAN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of HUTRAN.
    Type: Grant
    Filed: June 30, 1998
    Date of Patent: May 9, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Olga Bandman, Jennifer L. Hillman, Karl J. Guegler, Gina A. Gorgone, Neil C. Corley, Chandra Patterson
  • Patent number: 6057108
    Abstract: The invention provides human ARF-related proteins (HARP) and polynucleotides which identify and encode HARP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HARP.
    Type: Grant
    Filed: June 23, 1998
    Date of Patent: May 2, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Olga Bandman, Karl J. Guegler, Neil C. Corley, Henry Yue, Chandra Patterson
  • Patent number: 6057112
    Abstract: The present invention provides a human ubiquitin conjugation system protein (UCSP) and polynucleotides which encode UCSP. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of UCSP.
    Type: Grant
    Filed: April 16, 1999
    Date of Patent: May 2, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Neil C. Corley, Preeti Lal, Purvi Shah
  • Patent number: 6057140
    Abstract: The invention provides human SCAD family molecules (HSFM) and polynucleotides which identify and encode HSFM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSFM.
    Type: Grant
    Filed: June 30, 1998
    Date of Patent: May 2, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Karl J. Guegler, Gina A. Gorgone, Neil C. Corley, Mariah R. Baughn, Henry Yue
  • Patent number: 6057110
    Abstract: The present invention provides a polynucleotide (hhp) which identifies and encodes a novel human hyaluronidase (HHP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HHP. The invention also provides for the use of substantially purified HHP and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of HHP. Additionally, the invention provides for the use of antisense molecules to hhp in pharmaceutical compositions for treatment of diseases associated with the expression of HHP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of hhp. The present invention also relates to anti-HHP antibodies which specifically bind to HHP.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: May 2, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
  • Patent number: 6054290
    Abstract: The present invention provides a human vesicle binding protein (MVBP) and polynucleotides which identify and encode MVBP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing MVBP and for treating or preventing disorders associated with expression of MVBP.
    Type: Grant
    Filed: May 15, 1997
    Date of Patent: April 25, 2000
    Assignee: Incyte Pharamaceuticals, Inc.
    Inventors: Olga Bandman, Phillip R. Hawkins, Lynn E. Murry
  • Patent number: 6054292
    Abstract: The invention provides a human T-cell receptor protein (TCRLP) and polynucleotides which identify and encode TCRLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of TCRLP.
    Type: Grant
    Filed: July 18, 1997
    Date of Patent: April 25, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Neil C. Corley
  • Patent number: 6051692
    Abstract: The present invention provides a human retinoid binding protein (Hu-RBP) and polynucleotides which identify and encode Hu-RBP. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of Hu-RBP, as well as diagnostic assays.
    Type: Grant
    Filed: January 22, 1999
    Date of Patent: April 18, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Preeti Lal, Joanne R. Petithory
  • Patent number: 6051697
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel chemokine (EEC) expressed in human eosinophil cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode EEC, expression vectors for the production of purified EEC, antibodies capable of binding specifically to EEC, hybridization probes or oligonucleotides for the detection of EEC-encoding nucleotide sequences, genetically engineered host cells for the expression of EEC, diagnostic tests for chemokine activation based on EEC-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: April 18, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Roger Coleman, Susan G. Stuart
  • Patent number: 6048718
    Abstract: The present invention provides a human mitochondrial F6 subunit (HMF6) and polynucleotides which encode HMF6. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of HMF6.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: April 11, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Purvi Shah
  • Patent number: 6048970
    Abstract: The invention provides two human prostate growth-associated membrane proteins (PGAMP) and polynucleotides which identify and encode PGAMP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of PGAMP.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: April 11, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Karl J. Guegler, Neil C. Corley
  • Patent number: 6046029
    Abstract: The invention provides a human fatty acid synthase-like protein (HFASLP) and polynucleotides which identify and encode HFASLP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HFASLP.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: April 4, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Henry Yue, Neil C. Corley
  • Patent number: 6046027
    Abstract: The invention provides a human retinoid binding protein (RBPhu) and polynucleotides which identify and encode RBPhu. The invention also provides expression vectors, host cells, agonists, antibodies antagonists. The invention also provides methods for treating disorders associated with expression of RBPhu.
    Type: Grant
    Filed: July 22, 1997
    Date of Patent: April 4, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Karl J. Guegler, Purvi Shah
  • Patent number: 6046001
    Abstract: The invention provides human fatty acid beta-oxidation enzymes (HUFA) and polynucleotides which identify and encode HUFA. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUFA.
    Type: Grant
    Filed: December 31, 1997
    Date of Patent: April 4, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Jennifer L. Hillman, Karl J. Guegler, Neil C. Corley, Y. Tom Tang, Purvi Shah
  • Patent number: 6045792
    Abstract: The present invention provides novel human protein kinases (HPK) and polynucleotides which identify and encode HPK. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPK. The invention also provides for pharmaceutical compositions comprising HPK or antagonists of HPK, and antibodies which specifically bind HPK. Additionally, the invention provides antisense molecules to HPK for treatment or prevention of diseases associated with abnormal expression of HPK.
    Type: Grant
    Filed: July 7, 1998
    Date of Patent: April 4, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Karl J. Guegler, Phillip R. Hawkins
  • Patent number: 6046315
    Abstract: The invention provides a human disease associated calmodulin protein (DACP-1) and polynucleotides which identify and encode DACP-1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of DACP-1.
    Type: Grant
    Filed: November 3, 1997
    Date of Patent: April 4, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer Hillman, Purvi Shah, Neil C. Corley